US Stock Insider Trading | Liquidia disclosed two insider trading transactions on February 12

K-LinePoet · 2026-03-08T03:52:33+00:00

On February 12, 2026, Liquidia disclosed insider trading, with director Manning Paul B selling 55,100 shares on February 11. The company focuses on pulmonary hypertension treatment and conducts drug development using PRINT technology.

K-LinePoet

2026-03-08 03:52:33

Abstract generation in progress

On February 12, 2026, Liquidia (LQDA) disclosed two insider trading transactions. Director Manning Paul B sold 55,100 shares on February 11, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 12, 2026	Director	Manning Paul B	February 11, 2026	Buy	0	42.63	0.0000
January 28, 2026	Executive	Adair Jason	January 26, 2026	Sell	688	41.65	$28,700
January 28, 2026	Executive	Boyle Dana	January 26, 2026	Sell	1,580	41.65	$65,800
January 13, 2026	Executive	Schundler Russell	January 12, 2026	Sell	27,300	37.43	$1,021,400
January 13, 2026	Executive	Krepp Sarah	January 12, 2026	Sell	13,200	37.43	$492,800
January 13, 2026	Executive	Saggar Rajeev	January 12, 2026	Sell	21,100	37.43	$791,300
January 13, 2026	Director	JEFFS ROGER	January 12, 2026	Sell	66,600	37.43	$2,493,200
January 13, 2026	Executive	Boyle Dana	January 12, 2026	Sell	11,000	37.43	$413,500
January 13, 2026	Executive	Kaseta Michael	January 12, 2026	Sell	36,900	37.43	$1,382,400
January 13, 2026	Executive	Adair Jason	January 12, 2026	Sell	13,500	37.43	$507,100

[Company Information]

Liquidia Corporation was incorporated in Delaware on June 17, 2020. The company is a biopharmaceutical firm focused on the development, manufacturing, and commercialization of products addressing unmet patient needs, currently emphasizing treatments for pulmonary arterial hypertension. The company operates through two wholly owned subsidiaries, Liquidia Technologies and Liquidia PAH, as a single entity. Using expertise in cardiopulmonary diseases and proprietary PRINT technology—a particle engineering platform capable of precisely producing uniform drug particles—the company aims to improve the safety, efficacy, and performance of a broad range of therapies. Through collaborations with third parties in product development and research, the company has experience applying PRINT to various delivery methods and drug payloads, including inhalation therapies, vaccines, biologics, nucleic acids, and ophthalmic implants.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.